Stephen Harrison, MD
Family Medicine · Clinton, IANPI 1649221508
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Novo Nordisk AS at 31.9% of the total. Reporting peaked in 2021 at $70,877 and has fallen 99.0% since, to $674 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 826 payments — averaging $301.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$80K
- Novo Nordisk$76K
- Supernus Pharmaceuticals, Inc.$58K
- AbbVie$27K
- Ironshore Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$870
- plus $6K from 38 others
Across 1 payment — averaging $1125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1K
What the payments were for
- Consulting fees$141,37557%
- Speaking & faculty fees$74,13230%
- Travel & lodging$21,4839%
- Food & beverage$11,7555%
- Education$3700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$52,840
- VRAYLAR$25,092
- Jornay PM 20mg capsules (Bottle of 100)$1,630
How this compares
$249,115 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 580 | $223,616 |
| JardianceEmpagliflozin | 128 | $138,090 |
| OzempicSemaglutide | 82 | $83,993 |
| XareltoRivaroxaban | 157 | $78,968 |
| MyrbetriqMirabegron | 194 | $64,617 |
| JanuviaSitagliptin Phosphate | 87 | $49,250 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $45,663 |
| TrulicityDulaglutide | 34 | $32,203 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $30,659 |
| Potassium Chloride | 640 | $25,821 |
| CreonLipase/Protease/Amylase | 19 | $23,665 |
| MounjaroTirzepatide | 18 | $19,954 |
| Duloxetine Hcl | 482 | $14,514 |
| RexultiBrexpiprazole | 14 | $13,548 |
| Atorvastatin Calcium | 940 | $13,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $559 | $230,922614 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $34 | $147,886140 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $256 | $91,563154 claims |
| Novo NordiskOzempic | $75,878 | $83,99382 claims |
| Johnson & JohnsonXarelto | $257 | $78,968157 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $64,617194 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $396 | $52,15752 claims |
| AbbVieCreon, Fetzima | $26,698 | $28,99840 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $870 | $13,54814 claims |
| Sanofi-aventis U.S. LLCLantus | $101 | $9,10555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Clinton
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
- Matthew SmithWaterloo$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.